An Open-Label Study to Investigate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of RO7034067 in Adult and Pediatric Patients With Spinal Muscular Atrophy
Phase of Trial: Phase II
Latest Information Update: 13 Nov 2017
At a glance
- Drugs RG 7916 (Primary)
- Indications Spinal muscular atrophy
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Acronyms Jewelfish
- Sponsors Roche
- 07 Nov 2017 Planned End Date changed from 31 Jan 2021 to 5 Apr 2019.
- 07 Nov 2017 Planned primary completion date changed from 31 Jan 2020 to 5 Apr 2019.
- 16 Feb 2017 Status changed from not yet recruiting to recruiting.